Search Results

Jacobs was selected by FUJIFILM Diosynth Biotechnologies to support delivery of $1.2 billion expansion of an end-to-end, large-scale cell culture contract manufacturing site in Holly Springs, North Carolina.

FUJIFILM Diosynth Biotechnologies is offering unique opportunities to join one of the top global CDMOs focused on solving some of the most complex healthcare challenges.

FUJIFILM Diosynth Biotechnologies announced an agreement with argenx to manufacture efgartigimod, a monoclonal antibody fragment to target the neonatal Fc receptor, in patients with severe autoimmune disease.

Chimeron Bio, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, to advance the Company’s Oncology portfolio to the clinic.

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.

aTyr Pharma, Inc. (Nasdaq: LIFE), and FUJIFILM Diosynth Biotechnologies, today announced a manufacturing agreement for ATYR1923, aTyr Pharma’s lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

VolitionRx Limited has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd, a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed,